Coherus Oncology, Inc. filings document an oncology operating company with Nasdaq-listed common stock and disclosures tied to LOQTORZI commercialization, antibody immunotherapy development and capital formation. Form 8-K reports cover operating results and business updates, preliminary financial information, clinical supply arrangements involving tagmokitug, and equity transactions under shelf registration, at-the-market and underwritten public offering structures.
Proxy and other filings describe board elections, executive compensation, equity awards, shareholder voting matters, registered securities, governance practices, risk disclosures and the company's capital structure, including common stock issuance and offering-related agreements.
Coherus Oncology, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing. The company previously received a Nasdaq deficiency notice on June 30, 2025 after its common stock closed below $1.00 per share for 30 consecutive business days, giving it until December 29, 2025 to cure the issue.
On September 5, 2025, Nasdaq informed Coherus that the closing price of its common stock had been $1.00 or greater for the requisite period, restoring compliance with Listing Rule 5550(a)(2). Coherus is now in full compliance with all continued listing standards of the Nasdaq Global Market, removing the immediate risk associated with the prior deficiency notice.